CIK 0001479419
- Non-accelerated filer
- Smaller reporting company
KALA BIO, Inc.
Sign in to watch- Ticker
- KALA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 270604595
- Phone
- +1 781-996-5252
- Business address
- 1167 MASSACHUSETTS AVENUE, ARLINGTON, MA, 02476
- Former names
- KALA BIO, Inc., Kala Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-06-12 | Paull Robert Bradley Director | Grant or award · Stock Option (right to buy) | +12,960 | 12,960 | ||
| 2018-06-12 | Rosen Howard B Director | Grant or award · Stock Option (right to buy) | +12,960 | 12,960 | ||
| 2018-06-11 | Paull Robert Bradley Director | Other acquisition | +477 | 1,074 | ||
| 2018-05-18 | Paull Robert Bradley Director | Other acquisition | +597 | 597 | ||
| 2018-04-05 | Trachtenberg Eric General Counsel and Secretary | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2018-02-28 | PERRY GREGORY D Director | Grant or award · Stock Option (right to buy) | +25,920 | 25,920 | ||
| 2018-02-28 | Chen Hongming Chief Scientific Officer | Exercise or conversion | +4,000 | $2.30 | $9K | 50,080 |
| 2018-02-28 | Chen Hongming Chief Scientific Officer | Exercise or conversion | +5,769 | $2.24 | $13K | 55,849 |
| 2018-02-28 | Chen Hongming Chief Scientific Officer | Exercise or conversion · Stock Option (right to buy) | −4,000 | 106,236 | ||
| 2018-02-28 | Chen Hongming Chief Scientific Officer | Exercise or conversion · Stock Option (right to buy) | −5,769 | 0 | ||
| 2018-02-08 | ORBIMED ADVISORS LLC 10% owner | Purchase | +25,000 | $12.93 | $323K | 3,447,840 |
| 2018-02-07 | Bazemore Todd Chief Operating Officer | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2018-02-07 | Iwicki Mark T Chief Executive Officer | Grant or award · Stock Option (right to buy) | +230,000 | 230,000 | ||
| 2018-02-07 | Brazzell Romulus K Chief Medical Officer | Grant or award · Stock Option (right to buy) | +70,000 | 70,000 | ||
| 2018-02-07 | Chen Hongming Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +70,000 | 70,000 | ||
| 2018-02-07 | Reumuth Mary Chief Financial Officer | Grant or award · Stock Option (right to buy) | +70,000 | 70,000 | ||
| 2018-02-07 | LaRussa Michele Sr. VP, Regulatory and Quality | Grant or award · Stock Option (right to buy) | +8,000 | 8,000 | ||
| 2018-02-02 | ORBIMED ADVISORS LLC 10% owner | Purchase | +37,840 | $14.73 | $557K | 3,422,840 |
| 2018-02-01 | ORBIMED ADVISORS LLC 10% owner | Purchase | +22,840 | $14.99 | $342K | 3,385,000 |
| 2018-01-31 | ORBIMED ADVISORS LLC 10% owner | Purchase | +339,400 | $15.00 | $5.1M | 3,362,160 |
Page 20 of 24 · 472 trades